Krystal Biotech (NASDAQ:KRYS) Releases Earnings Results, Beats Estimates By $0.07 EPS

Krystal Biotech (NASDAQ:KRYS) announced its quarterly earnings data on Monday. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07, Briefing.com reports. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. During the same period in the prior year, the firm posted ($0.67) EPS. The company’s revenue was up 879.9% on a year-over-year basis.

Krystal Biotech Trading Up 5.0 %

Shares of KRYS traded up $8.68 during midday trading on Wednesday, reaching $183.09. 609,984 shares of the company were exchanged, compared to its average volume of 181,472. Krystal Biotech has a 1-year low of $93.95 and a 1-year high of $219.34. The company has a market cap of $5.26 billion, a price-to-earnings ratio of 103.44 and a beta of 0.82. The stock has a 50-day moving average price of $181.39 and a 200-day moving average price of $180.25.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 14.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on KRYS shares. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Tuesday. Evercore ISI increased their target price on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Chardan Capital upped their price target on Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Finally, Citigroup lifted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $197.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).